CapsoVision, Inc. (CV)

CapsoVision's stock experienced several events in the past six months. In December 2025, shares rose after filing a 510(k) application with the FDA. In January 2026, the company reported its Second Quarter 2025 Financial Results. In March 2026, CapsoVision reported its financial results for the fourth quarter and full year ended December 31, 2025, which included a 13% increase in fourth-quarter revenue and a 15% increase in full-year revenue, and completed a $14 million private placement of public equity financing. As of April 7, 2026, the stock price was $6.26, with a market capitalization of $312 million.

Information regarding the specific demand seasonality for CapsoVision, Inc.'s products and services is not available in the provided search results.

CapsoVision, Inc. is a medical technology company specializing in advanced imaging and AI technologies for endoscopy solutions, focusing on capsule endoscopy within the healthcare sector. Its major products include CapsoCam Plus, CapsoCloud, CapsoView, CapsoAccess, CapsoRetrieve, and CapsoCam Colon. The company was founded in 2005, is headquartered in Saratoga, California, and became publicly held on July 2, 2025.

CapsoVision, Inc. is headquartered in Saratoga, California, United States, and has a foreign branch in Taiwan, Republic of China.

CapsoVision's brand reputation has been positively influenced by its technological advancements and regulatory progress, particularly the FDA application for an AI-assisted module for CapsoCam Plus, which led to a rise in its shares in December 2025. The company's focus on developing advanced imaging and AI-enabled solutions for gastrointestinal disease detection and screening, along with the expansion of CapsoCam Plus adoption and progress on pipeline products like CapsoCam Colon, contribute to its reputation as an innovator in the medical technology space.

CapsoVision, Inc. is a publicly held company that was formerly venture capital-backed. Accredited investors can buy pre-IPO stock through EquityZen funds, made available by existing shareholders.